[{"orgOrder":0,"company":"NCK AS","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Berubicin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"NCK AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NCK AS \/ NCK A\/S.","highestDevelopmentStatusID":"8","companyTruncated":"NCK AS \/ NCK A\/S."},{"orgOrder":0,"company":"Nichi-Iko Pharmaceutical","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Limaprost Alfadex","moa":"PGE2","graph1":"Neurology","graph2":"Approved","graph3":"Nichi-Iko Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nichi-Iko Pharmaceutical \/ Nichi-Iko Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Nichi-Iko Pharmaceutical \/ Nichi-Iko Pharmaceutical"},{"orgOrder":0,"company":"OncoGenerix USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Peptide vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OncoGenerix USA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"OncoGenerix USA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoGenerix USA \/ Not Applicable"},{"orgOrder":0,"company":"Nichi-Iko Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nichi-Iko Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Nichi-Iko Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nichi-Iko Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"MEDILINK PHARMACHEM","sponsor":"Apricot Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Series A Financing","leadProduct":"Antibody-drug conjugate","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MEDILINK PHARMACHEM","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"MEDILINK PHARMACHEM \/ Apricot Capital","highestDevelopmentStatusID":"4","companyTruncated":"MEDILINK PHARMACHEM \/ Apricot Capital"},{"orgOrder":0,"company":"Veracyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Apalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veracyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Veracyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veracyte \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Sundia MediTech Company

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Notably, the addition of apalutamide to ADT improved the MFS percentage among the Decipher high-risk patients to a level similar to the percentage among patients classified as Decipher low-to-average-risk.

                          Brand Name : ARN-509

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 14, 2021

                          Lead Product(s) : Apalutamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The series A financing will help in accelerating Medilink's innovative pipeline development and to support its unique conjugate technology platform.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 01, 2021

                          Lead Product(s) : Antibody-drug conjugate

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Apricot Capital

                          Deal Size : $50.0 million

                          Deal Type : Series A Financing

                          blank

                          03

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The full results of the large randomised clinical trial released in the New England Journal of Medicine confirmed the benefits for people with advanced or moderate disease.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 22, 2020

                          Lead Product(s) : Dexamethasone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Nichi-Iko will convert the formulation of “Limaprost Alfadex tablets 5 µg to a formulation which has been improved for moisture resistance stability following the technology transfer.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 05, 2020

                          Lead Product(s) : Limaprost Alfadex

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Recipient : Ono Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : OncoGen researchers propose a novel approach for producing epitope-based peptide vaccine candidates for the novel China coronavirus (nCoV).

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          January 28, 2020

                          Lead Product(s) : Peptide vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : For the large scale production of Berubicin, its lead drug candidate for the treatment of glioma brain tumors.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 14, 2020

                          Lead Product(s) : Berubicin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : CNS Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank